A topical medication, Флукорт Н is applied in clinical settings that involve acute or unstable symptom patterns, particularly where a patient's inflammatory skin condition is complicated by a bacterial component. This type of combination therapy is commonly used for short-term periods when a bacterial skin infection is present alongside inflammation.

The medication is considered relevant within therapeutic domains involving conditions characterized by periods of heightened symptoms, such as various eczemas, dermatitis, and certain forms of psoriasis, when these exhibit signs of secondary infection. It supports the patient by addressing symptom clusters across both inflammatory and microbial domains. The therapeutic benefit is to deliver supportive symptomatic relief, which contributes to improved comfort during periods of heightened symptoms.

“This approach is relevant for easing symptoms that create noticeable physiological strain, particularly severe pruritus (intense itching) and pronounced redness and swelling.”

It helps ease the overall symptom load and may help patients cope more steadily with difficult episodes, providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Support for Infected Eczematous Flares

Use of Флукорт Н is defined by strict population eligibility rules outlined in regulatory documents for its combination components (Fluocinolone Acetonide and Neomycin).

Absolute Contraindications

The medicine must not be used by patients with a known hypersensitivity or allergy to Fluocinolone Acetonide, Neomycin, or any component of the cream. It is also contraindicated in cases of primary viral, fungal, or mycobacterial skin infections at the treatment site, as well as for conditions like Acne vulgaris, Rosacea, or Perioral dermatitis. Application near the ear is prohibited if the patient has a perforated eardrum.

Restricted or Conditional Use

• Pediatric Use: Use in children is restricted due to a greater risk of systemic toxicity and potential HPA axis suppression. Occlusive dressings such as tight diapers must not be used during treatment.
• Pregnancy and Lactation: Use during pregnancy is restricted (Category C); it should only be used if the potential benefit outweighs the risk. Caution is required during lactation, and the cream must not be applied to the breast/nipple area.
• Comorbidities: Caution is required for patients with pre-existing conditions, including Cushing's syndrome (adrenal disorder), diabetes, and hyperglycemia, as the potent corticosteroid may affect these conditions. Use is also restricted over large areas of broken skin.

Interactions with other medicines and products

The interaction profile for Флукорт Н is primarily defined by the potential for systemic absorption of the active ingredients, Fluocinolone Acetonide and Neomycin, which may lead to pharmacodynamic reinforcement with other agents. The risk of interaction is tied to conditions that increase systemic exposure, such as application under occlusive dressings or over extensive body surface areas.

The Neomycin component carries a risk of additive organ toxicity. Regulatory documents mandate avoidance of concurrent or sequential use with other neurotoxic or nephrotoxic agents, including potent diuretics such as Furosemide, as these can enhance Neomycin toxicity and increase the risk of ototoxicity. The product is also contraindicated for use in the external auditory canal if the eardrum is perforated, as this condition dramatically increases toxic exposure.

The corticosteroid component may lead to hyperglycemia or glucosuria upon systemic absorption, a pharmacodynamic effect that can antagonize the therapeutic action of co-administered antidiabetic agents. Special consideration is required for pediatric patients due to their increased surface area-to-mass ratio, and for patients with pre-existing renal dysfunction, who face a heightened risk of Neomycin-associated toxicity due to altered drug clearance. This structure aligns with the documented regulatory classifications for exposure-dependent topical agents.

Флукорт Н is a combination agent containing fluocinolone acetonide and clioquinol. Fluocinolone acetonide, a synthetic glucocorticoid, acts as an agonist at the cytosolic glucocorticoid receptor (GR), primarily within dermal cells. Upon ligand binding, the steroid-GR complex translocates into the cell nucleus. Here, it binds to glucocorticoid response elements (GREs) on target gene promoters, modulating gene transcription. This genomic action leads to the induced expression of lipocortins (Annexin A1), which are phospholipase A2 ( PLA2) inhibitory proteins. The inhibition of PLA2 diminishes the release of arachidonic acid, subsequently suppressing the biosynthesis of potent inflammatory mediators such as prostaglandins and leukotrienes (eicosanoid cascade inhibition). System-level consequences include local vasoconstriction and a reduction in vascular permeability and cellular proliferation. Concurrently, clioquinol exerts effects via metal ion chelation, specifically binding essential ions like copper and zinc. This chelation disrupts enzymatic processes vital for susceptible microbial cell wall integrity and DNA synthesis, thereby hindering their cellular propagation.

How to Use Флукорт Н — Administration Guidelines

This section outlines the administration instructions for Флукорт Н (Fluocinolone Acetonide/Neomycin cream), focusing on procedural usage and constraints.

Administration Scope

The preparation is for topical application and external use only. Standard dosing involves applying a thin film of the cream to the affected area. The frequency of application generally ranges from two to four times daily, with the specific schedule adjusted based on the severity of the condition.

Use is restricted to short-term courses, often stipulated as not exceeding 14 days, and treatment is discontinued once the desired control of the condition is achieved. Administration of Флукорт Н requires special attention to avoid contact with the eyes.

Population and Procedural Constraints

Specific constraints relate to absorption risk. For pediatric patients, use is limited to the least effective amount and shortest duration possible. A critical instruction for infants treated in the diaper area is the prohibition of occlusive dressings (e.g., tight-fitting diapers or plastic pants) over the treated area, as this significantly increases the systemic absorption of the corticosteroid component.

When applying the cream to hairy sites, the hair must be parted to ensure that the medication makes direct contact with the lesion. Although occlusive bandaging may be considered for resistant skin conditions, its use must be discontinued if there are signs of a suspected local infection.

Connection to the Overall Use Protocol

These instructions establish a defined protocol for the topical administration of this combination product. The short-term use and the restrictions on occlusive methods structure the overall course of use, primarily to govern the patient's systemic exposure to the corticosteroid ingredient.

Research Evidence / Overview of Studies for Флукорт Н

Evidence for Use in Infected Dermatoses

Research for this combination cream was studied for Corticosteroid-Responsive Dermatoses Complicated by Secondary Bacterial Infection. This body of evidence includes inflammatory skin conditions, such as eczema and dermatitis, where a bacterial component is a factor. The research explored the medicine primarily through short-term Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies were designed to compare the fixed combination product against the anti-inflammatory component (the corticosteroid) used alone, allowing researchers to examine the comparative outcomes measured for the combination versus the corticosteroid component alone.

Studies have monitored outcomes linked to inflammatory or irritative states. Researchers measured changes in the overall skin condition using standardized scoring tools to track the severity of physical discomfort and the visible signs of inflammation. Findings describe patterns observed in the studies where the combination was evaluated in studies observing responses over defined time intervals. Evidence describes patterns related to Global Clinical Improvement assessments and standardized disease scoring tools.

Long-Term Studies and Follow-up Duration

Research primarily explored short-term symptom changes during periods of increased symptom activity, with follow-up durations that were limited. This means that research has explored outcomes related to episodic or acute changes but has not examined evidence related to extended durability of effect.

Long-term effects are not fully established in the available research. Evidence highlights what is known—and what is still uncertain—about outcomes over extended periods.

Evidence in Specific Patient Groups

Studies exploring short-term symptom changes have included both adults and children, with some trials including children as young as 6 months of age who were studied for conditions involving periods of heightened symptoms. The results apply only to the populations studied. Scientific literature indicates that data for certain groups remain insufficient, and subgroup findings are uncertain for populations not typically represented in the main trials.

Evidence Quality and Research Gaps

Evidence quality varies across studies that address the use of topical corticosteroid and antibiotic combinations. Systematic reviews sometimes categorize the certainty of the findings as low. A key limitation is that comparative evidence is lacking, particularly regarding the comparison of the combination product to the corticosteroid component alone after the first week of assessment. It is not yet clear whether the fixed antibiotic component is necessary for outcomes observed beyond the initial short-term assessment window, and data are still emerging.

Key Studies & References

1. Topical Corticosteroids and Antibiotics (StatPearls Review)
2. Drug Monograph: Fluocinolone Acetonide and Neomycin Sulphate Cream (Representative Regulatory Document)

Common questions about Флукорт Н (FAQ)

Q: What is the proper way to dispose of the unused Флукорт Н tube?

Regulatory guidelines indicate that unused or expired Флукорт Н should be discarded safely. The preferred method is generally to use a drug take-back program if one is available in your area. If a take-back program cannot be accessed, official instructions advise mixing the cream with an undesirable substance, like used coffee grounds or cat litter, placing the mixture in a sealed container, and discarding it in the household trash. It is also generally advised to remove or scratch out all personal information on the empty packaging.

Q: Does Флукорт Н kill the bacteria that cause skin infections?

The Флукорт Н combination product is formulated to address bacterial involvement in skin conditions. Official product information states that the Neomycin component is an aminoglycoside antibiotic. This ingredient is described as interfering with the growth of susceptible bacteria, which helps control the microbial load in the affected skin area.

Q: Where should I store my Флукорт Н cream?

According to official product information, Флукорт Н should be kept at controlled room temperature, which is typically between 15 C and 25 C (59 F to 77 F). The container should be kept tightly closed and protected from direct sunlight, excessive heat, and moisture. The product is not to be frozen.

Q: How should I clean the skin before applying Флукорт Н?

While the drug label focuses on application, general patient information for topical treatments is often advised. This guidance typically suggests that hands be washed with soap and water both before and after applying the medication. The skin area to be treated should be clean before the cream is applied as a thin film.

Q: What should I do if I miss a dose of the cream?

Official patient information indicates that if a dose is missed, applying it as soon as it is remembered is generally advised. However, if it is already close to the time for the next scheduled application, the missed dose is usually skipped, and the regular schedule is continued. Applying extra cream to compensate for the missed dose is not advised.

Q: How long after I start using it will I notice improvement in my skin?

Studies and official information indicate that this combination cream is intended for short-term use. Treatment should be discontinued once the desired control over the skin condition is achieved. If control of the condition is not achieved or if no improvement is observed after a defined period, reassessment by a healthcare professional is considered necessary.

Q: Does Флукорт Н cream sting or burn when I apply it?

Official documents list burning and irritation among the possible local adverse reactions for this product. Official instructions advise that if a severe reaction is experienced (such as intense stinging, burning, or a rash), the medication should be stopped and a healthcare professional should be contacted.

How to Store and Dispose of Флукорт Н

The storage and disposal of Флукорт Н (Fluocinolone Acetonide/Neomycin) cream must strictly follow regulatory requirements to maintain product stability and ensure safety.

Storage Requirements

Disposal Instructions

Unused or expired medication should be discarded according to official instructions, which often recommend using a drug take-back program or authorized collector. The product must not be flushed down a toilet or poured down a drain unless explicitly directed to do so by the regulatory label. If a take-back program is unavailable, follow specific guidelines for mixing the product with an undesirable substance before placing it in the household trash.